Product Reports Resources Pricing Login Book a demo

Castle Biosciences

Biotech & Life Sciences · Friendswood, United States · Founded 2008 · IPO 2019

Castle Biosciences develops and validates diagnostic tests and technologies for the treatment of cancer

Valuation $625M
Revenue $366M
Power Law Thoroughbred$100M+ revenue

Talent graph

Castle Biosciences's talent

Book a demo to see the people
Employees mapped 772 incl. 6 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on Castle Biosciences's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 1 investor entered at this stage
First Round Capital
Series A 1 investor entered at this stage
HealthQuest Capital
Series B+ 2 investors entered at this stage
Industry Ventures
BrightEdge

Global footprint

Where Castle Biosciences has talent and traffic

Workforce by country
4 countries with
team presence
🇺🇸 United States99.3%
🇬🇧 United Kingdom0.2%
🇦🇺 Australia0.2%
🇵🇪 Peru0.2%
4 countries shown
Web traffic by country
24K monthly visits
across markets
🇺🇸 United States88.3%
🇬🇧 United Kingdom6.3%
🇨🇦 Canada3.3%
🇵🇭 Philippines1.3%
🇮🇳 India0.4%
Top 5 markets shown

Patent intelligence

Castle Biosciences’s patent portfolio

Estimated portfolio value
$23M

18 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Capital deployed

Castle Biosciences's 4 investments and acquisitions.

Every disclosed deal where Castle Biosciences appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Castle Biosciences's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Castle Biosciences deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Castle Biosciences's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Castle Biosciences

        An AI-synthesized read of the highest-engagement posts about Castle Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Castle Biosciences on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles